menu
    • menu

    Company profile for Azafaros

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with diseasemodifying potential. Based on discoveries from Leiden University and Amsterdam UMC, Azafaros' proprietary lead compound AZ-3102 will initially address inherited life-threatening lysosomal storage diseases for which there are no...
    Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with diseasemodifying potential. Based on discoveries from Leiden University and Amsterdam UMC, Azafaros' proprietary lead compound AZ-3102 will initially address inherited life-threatening lysosomal storage diseases for which there are no effective therapies today. This orally available azasugar compound interferes with the metabolism of glycolipids and uniquely affects several key disease pathways through a dual mode of action.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AzafarosNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    J.H. Oortweg 21 2333 CH Leiden The Netherlands
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.azafaros.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Azafaros Publishes Nizubaglustat Data for GM2 Gangliosidosis
    Azafaros Publishes Nizubaglustat Data for GM2 Gangliosidosis

    25 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260224958744/en/Azafaros-Announces-Publication-of-Preclinical-Efficacy-Data-with-Nizubaglustat-in-GM2-Gangliosidosis

    BUSINESSWIRE
    25 Feb 2026
    Share Share
    Azafaros Presents Nizubaglustat Data At Worldsymposium 2026
    Azafaros Presents Nizubaglustat Data At Worldsymposium 2026

    22 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260121361664/en/Azafaros-Announces-Key-Scientific-Oral-and-Poster-Presentations-on-Nizubaglustat-Accepted-for-WORLDSymposium-2026

    BUSINESSWIRE
    22 Jan 2026
    Share Share
    Azafaros Boosts Board With Biotech Entrepreneur Dr. Thierry
    Azafaros Boosts Board With Biotech Entrepreneur Dr. Thierry

    11 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251210848919/en/Azafaros-Further-Strengthens-Its-Board-of-Directors-With-Appointment-of-Biotech-Entrepreneur-Dr.-Thierry-Abribat

    BUSINESSWIRE
    11 Dec 2025
    Share Share
    Azafaros Starts Ph 3 for Niemann-Pick disease and Gangliosidoses
    Azafaros Starts Ph 3 for Niemann-Pick disease and Gangliosidoses

    28 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250727003310/en/Azafaros-Announces-Initiation-of-two-Global-Phase-3-studies-with-Nizubaglustat-in-Niemann-Pick-disease-Type-C-NPC-and-GM1GM2-gangliosidoses-respectively

    BUSINESSWIRE
    28 Jul 2025
    Share Share
    Azafaros to Present at BIO After €132M Series B Success
    Azafaros to Present at BIO After €132M Series B Success

    09 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250608410983/en/Azafaros-to-Present-at-BIO-International-Convention-2025-Following-Successful-%E2%82%AC132M-Series-B-Financing

    BUSINESSWIRE
    09 Jun 2025
    Share Share
    Dutch biotech gets $146M for late-stage trials in three metabolic disorders
    Dutch biotech gets $146M for late-stage trials in three metabolic disorders

    13 May 2025

    // ENDPTS

    https://endpts.com/dutch-biotech-azafaros-gets-146m-for-phase-3-trials-in-three-metabolic-disorders/

    ENDPTS
    13 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search